- Hayward, CA-based Arcus Biosciences (NYSE:RCUS) has filed a prospectus for a $100M IPO.
- The clinical-stage biopharmaceutical firm develops cancer immunotherapies targeting well-characterized biological pathways for which there are no molecules in development or the ones that exist have less-than-desired profiles. Its initial focus is on the ATP-adenosine pathway, a key driver of immunosuppression in the tumor microenvironment. Lead candidate is small molecule AB928, an adenosine receptor antagonist.
-
2017 Financials ($M): Operating Expenses: 54.9 (+201.6%); Net Loss: (53.1) (-195.0%); Cash Burn: (25.1) (-94.6%).
-
Update: It amended prospectus specifies an offering of 7.1M shares of common stock at $13 - 15.